This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry
Author(s): Martin E. Gleave, Michael E. Cox, Yuzhuo Wang (auth.), William D. Figg, Cindy H. Chau, Eric J. Small (eds.)
Edition: 1
Publisher: Springer-Verlag New York
Year: 2010
Language: English
Pages: 430
Tags: Oncology; Urology/Andrology; Internal Medicine
Front Matter....Pages i-xvii
Front Matter....Pages 25-25
Cell Biology of Prostate Cancer and Molecular Targets....Pages 1-24
Front Matter....Pages 25-25
Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer....Pages 27-39
Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer....Pages 41-51
Androgens and Prostate Cancer....Pages 53-59
Androgen Receptor Biology in Prostate Cancer....Pages 61-70
Androgen Receptor Antagonists....Pages 71-81
5-Alpha Reductase Inhibitors in Prostate Cancer....Pages 83-89
Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer....Pages 91-100
Androgen Deprivation Therapy....Pages 101-107
Pharmacogenetics of the Androgen Metabolic Pathway....Pages 109-121
Front Matter....Pages 123-123
Mitoxantrone....Pages 125-131
Docetaxel....Pages 133-146
Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer....Pages 147-151
Platinum Agents in Prostate Cancer....Pages 153-161
Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer....Pages 163-177
Microtubule Targeting Agents....Pages 179-194
Front Matter....Pages 195-195
Principles of Antiangiogenic Therapy....Pages 197-205
Bevacizumab in Advanced Prostate Cancer....Pages 207-214
Thalidomide and Analogs....Pages 215-223
Investigational Angiogenesis Inhibitors....Pages 225-232
Front Matter....Pages 195-195
Pharmacogenetics of Angiogenesis....Pages 233-242
Front Matter....Pages 243-243
Pathophysiology of Prostate Cancer Bone Metastasis....Pages 245-254
Radiopharmaceuticals....Pages 255-266
Bisphosphonates for Prevention and Treatment of Bone Metastases....Pages 267-275
Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer....Pages 277-286
Calcitriol and Vitamin D Analogs....Pages 287-302
Front Matter....Pages 303-303
Cancer Immunology, Immunotherapeutics, and Vaccine Approaches....Pages 305-319
Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer....Pages 321-328
GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX....Pages 329-342
CTLA-4 Blockade for Prostate Cancer Treatment....Pages 343-348
Front Matter....Pages 349-349
Prostate Cancer Chemoprevention Strategies....Pages 351-362
Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk....Pages 363-373
Inflammation as a Target in Prostate Cancer....Pages 375-386
Front Matter....Pages 387-387
Challenges for the Development of New Agents in Prostate Cancer....Pages 389-397
FDA Approval of Prostate Cancer Treatments....Pages 399-405
Applications of Proteomics in Prostate Cancer....Pages 407-417
Erratum to: Docetaxel....Pages E1-E1
Back Matter....Pages 419-428
